Literature DB >> 1100130

Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

S J Pocock, R Simon.   

Abstract

In controlled clinical trials there are usually several prognostic factors known or thought to influence the patient's ability to respond to treatment. Therefore, the method of sequential treatment assignment needs to be designed so that treatment balance is simultaneously achieved across all such patients factor. Traditional methods of restricted randomization such as "permuted blocks within strata" prove inadequate once the number of strata, or combinations of factor levels, approaches the sample size. A new general procedure for treatment assignment is described which concentrates on minimizing imbalance in the distributions of treatment numbers within the levels of each individual prognostic factor. The improved treatment balance obtained by this approach is explored using simulation for a simple model of a clinical trial. Further discussion centers on the selection, predictability and practicability of such a procedure.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1100130

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  561 in total

1.  Microcomputer voice-response telephone entry for balanced clinical trial randomization.

Authors:  S Cheung; S M Entine; J H Klotz
Journal:  J Med Syst       Date:  1977       Impact factor: 4.460

2.  Comparison of balanced and random allocation in clinical trials: a simulation study.

Authors:  M M Rovers; H Straatman; G A Zielhuis
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

3.  A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

Authors:  Kevin B Kim; Victor Prieto; Richard W Joseph; Abdul H Diwan; Gary E Gallick; Nicholas E Papadopoulos; Agop Y Bedikian; Luis H Camacho; Patrick Hwu; Chaan S Ng; Wei Wei; Marcella M Johnson; Sabine M Wittemer; Anna Vardeleon; Aaron Reckeweg; A Dimitrios Colevas
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

4.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

5.  Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts.

Authors:  Jaeil Ahn; Suyu Liu; Wenyi Wang; Ying Yuan
Journal:  Biometrics       Date:  2013-11-06       Impact factor: 2.571

6.  Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

Authors:  J L Lefebvre; F Rolland; M Tesselaar; E Bardet; C R Leemans; L Geoffrois; P Hupperets; L Barzan; D de Raucourt; D Chevalier; L Licitra; F Lunghi; R Stupp; D Lacombe; J Bogaerts; J C Horiot; J Bernier; J B Vermorken
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

7.  Physical Activity and Lymphedema (the PAL trial): assessing the safety of progressive strength training in breast cancer survivors.

Authors:  Kathryn H Schmitz; Andrea B Troxel; Andrea Cheville; Lorita L Grant; Cathy J Bryan; Cynthia R Gross; Leslie A Lytle; Rehana L Ahmed
Journal:  Contemp Clin Trials       Date:  2009-01-08       Impact factor: 2.226

8.  Effect of an Intervention for Obesity and Depression on Patient-Centered Outcomes: An RCT.

Authors:  Lisa G Rosas; Kristen M J Azar; Nan Lv; Lan Xiao; Jeremy D Goldhaber-Fiebert; Mark B Snowden; Elizabeth M Venditti; Megan M Lewis; Andrea N Goldstein-Piekarski; Jun Ma
Journal:  Am J Prev Med       Date:  2020-02-14       Impact factor: 5.043

9.  [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].

Authors:  J Lehmann; M Retz; G Steiner; P Albers; E Jaeger; A Knuth; C Lippert; M Koser; K Stockamp; C Otto; H Melchior; C Fassmann; C Potratz; T Loch; H G Derigs; T Becker; T Kälble; H-J Piechota; L Hertle; S Weinknecht; L Weissbach; M Al-Mwalad; A Hamza; H Henss; D Brkovic; S Pomer; J Roloff; P Walz; R Muschter; U Tunn; E Winter; P Bub; U Kaldenbach; S Roth; A Brauers; G Jakse; A E Richter; M Wirth; J Hartlapp; H Van Ahlen; M Stöckle
Journal:  Urologe A       Date:  2003-04-02       Impact factor: 0.639

10.  Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Authors:  John C Araujo; Géralyn C Trudel; Fred Saad; Andrew J Armstrong; Evan Y Yu; Joaquim Bellmunt; George Wilding; John McCaffrey; Sergio V Serrano; Vsevolod B Matveev; Eleni Efstathiou; Stephane Oudard; Michael J Morris; Bruce Sizer; Peter J Goebell; Axel Heidenreich; Johann S de Bono; Stephen Begbie; Jun H Hong; Eduardo Richardet; Enrique Gallardo; Prashni Paliwal; Susan Durham; Shinta Cheng; Christopher J Logothetis
Journal:  Lancet Oncol       Date:  2013-11-08       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.